Lee Ainslie Verona Pharma PLC Transaction History
Maverick Capital LTD
- $4.82 Billion
- Q3 2024
A detailed history of Lee Ainslie (Maverick Capital LTD) transactions in Verona Pharma PLC stock. As of the latest transaction made, Maverick Capital LTD holds 4,215,973 shares of VRNA stock, worth $260 Million. This represents 2.52% of its overall portfolio holdings.
Number of Shares
4,215,973
Previous 3,092,807
36.32%
Holding current value
$260 Million
Previous $44.7 Million
171.22%
% of portfolio
2.52%
Previous 0.88%
Shares
4 transactions
Others Institutions Holding VRNA
# of Institutions
178Shares Held
68.6MCall Options Held
704KPut Options Held
685K-
Perceptive Advisors LLC New York, NY6.32MShares$389 Million4.75% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$344 Million12.27% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.01MShares$309 Million2.01% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$219 Million14.95% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$208 Million5.24% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $3.75B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...